Table 2.
First line options which are considered standard of care
Recommendations | Level of Evidence (LoE) | Grade of recommendation | Grade of consensus |
---|---|---|---|
Offer axitinib + pembrolizumab to treatment-naïve patients with any IMDC-risk category | 1 − | A | Strong |
Physicians may offer axitinib + avelumab to treatment-naïve patients with any IMDC-risk category | 1 − | B | Consensus |
Offer ipilimumab + nivolumab to treatment-naïve patients with intermediate or poor IMDC-risk category | 1 − | A | Strong |